Search Result

Results for "

epidermal growth factor receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	EGFR (61) IGF-1R (1) VEGFR (1) Antibody-Drug Conjugates (ADCs) (5) Apoptosis (5) BMX Kinase (1) Bradykinin Receptor (1) Btk (2) Calcium Channel (2) CDK (1) ERK (3) FAK (3) GPR35 (1) MEK (1) Neurokinin Receptor (1) PD-1/PD-L1 (1) Phosphatase (2) PROTACs (5) PTEN (1) Radionuclide-Drug Conjugates (RDCs) (1) Reactive Oxygen Species (2) Src (1) TAM Receptor (1) Thymidylate Synthase (1) Topoisomerase (3)
By Research Areas:	Cancer (66) Endocrinology (1) Inflammation/Immunology (4) Metabolic Disease (2) Neurological Disease (3)
Click Chemistry:	Alkynes (6)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Targets Recommended: EGFR FGFR GHR VEGFR TGF-beta/Smad PDGFR TGF-β Receptor GHSR IGF-1R Nuclear Hormone Receptor 4A/NR4A

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-132259

Depatuxizumab mafodotin ABT-414	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Depatuxizumab mafodotin is an antibody-drug conjugate (ADC) that specifically targets the epidermal growth factor receptor (EGFR). Depatuxizumab mafodotin can be used for cancer research .

HY-18963

Lavendustin A RG-14355	EGFR	Cancer
Lavendustin A (RG-14355) is a potent, selective and ATP-competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, with an IC₅₀ of 11 nM. Lavendustin A does not inhibit protein kinase A or C. Lavendustin A can suppress VEGF-induced angiogenesis .

HY-144680

BLU-945 ZL-2313	EGFR	Cancer
BLU-945 is a potent, highly selective, reversible and orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKIs). BLU-945 can effectively inhibit EGFR with L858R and/or exon 19 deletion mutation, T790M mutation and C797S mutation. BLU-945 can be used for the research of lung cancer including non-small cell lung cancer (NSCLC) .

HY-U00002

ZD-4190	VEGFR EGFR	Cancer
ZD-4190 is a potent, orally available inhibitor of the vascular endothelial cell growth factor receptor 2 (VEGFR2) and of epidermal growth factor receptor (EGFR) signalling, used for the treatment of cancer.

HY-131864

SJF-1528	EGFR PROTACs	Cancer
SJF-1528 is a potent EGFR PROTAC degrader with DC₅₀ values of 39.2 nM and 736.2 nM for wild-type EGFR in OVCAR8 cells and Exon 20 Ins mutated EGFR in HeLa cells. SJF-1528 also degrades HER2 (Pink: ligand for target protein (HY-159047); Black: linker Tos-PEG2-CH2-Boc (HY-130532); Blue: ligand for E3 ligase (S,R,S)-AHPC (HY-125845)) .

HY-P1085

Epidermal Growth Factor Receptor Peptide (985-996)	EGFR	Cancer
Epidermal Growth Factor Receptor Peptide (985-996) is an amino acid peptide fragment derived from positions 985-996 in epidermal growth factor receptor (EGFR) .

HY-164718

Sevabertinib	EGFR	Cancer
Sevabertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with antitumor activity .

HY-150782

UNC-CA359	EGFR	Cancer
UNC-CA359 is a potent **epidermal growth factor receptor (EGFR) inhibitor, with an IC₅₀** value of 18 nM. UNC-CA359 exhibits strong anti-tumor activity, can be used to Chordoma research . UNC-CA359 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-122347

Orvepitant GW823296	Neurokinin Receptor	Neurological Disease
Orvepitant (GW823296) is a compound with the ability to inhibit pruritus induced by cancer epidermal growth factor receptor inhibitor (EGFRI) and is a neurokinin-1 receptor antagonist.

HY-160613

EGFR/HER2-IN-11	EGFR	Cancer
EGFR/HER2-IN-11 (compound 20) is an orally active dual inhibitor for human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), with IC₅₀s of 7.7 and 22 nM, respectively. EGFR/HER2-IN-11 exhibits antitumor efficacy and inhibits proliferation against cancer cells BT-474 with GI₅₀ of 601 nM .

HY-12806

AG1557	EGFR	Cancer
AG1557 is a specific and ATP competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, has a pIC₅₀ value of 8.194 .

HY-115716

EGFR-IN-17	EGFR	Cancer
EGFR-IN-17 is a potent and selective inhibitor of the **epidermal growth factor receptor ( IC₅₀** 0.0002 μM) to overcome C797S-mediated resistance.

HY-114667

Lavendustin C6	EGFR	Others
Lavendustin C6 is a specific inhibitor of tyrosine kinase. Lavendustin C6 inhibits epidermal growth factor (EGF) receptor tyrosine kinase with an EC₅₀ value of 0.05 μg/mL. Lavendustin C6 inhibits platelet-derived growth factor (PDGF)-induced inositol phosphate formation .

HY-15772S3

Asandeutertinib asandeutertinibum; Osimertinib-d₃; AZD-9291-d₃	EGFR	Cancer
Asandeutertinib (Osimertinib-d3; AZD-9291-d3) is a epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, with antineoplastic effect .

HY-P9905

Cetuximab Maximum Cited Publications 33 Publications Verification C225	Radionuclide-Drug Conjugates (RDCs) EGFR	Cancer
Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a K_d of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity .

HY-164527

Si306	Src FAK EGFR	Cancer
Si306 is a Src inhibitor with antitumor activity. Si306 reduces the phosphorylation of focal adhesion kinase (FAK) and the expression of epidermal growth factor receptor (EGFR), and inhibits the invasion of human glioblastoma (GBM) .

HY-101958

Tyrphostin 25 AG82; Tyrphostin A 25; Tyrphostin AG 82; RG-50875	EGFR GPR35	Inflammation/Immunology Cancer
Tyrphostin 25 (AG82) is a specific inhibitor of the EGFR tyrosine kinase. Tyrphostin 25 is also a GPR35 agonist with an IC₅₀ of 0.94 µM and an EC₅₀ of 5.3 µM .

HY-114456

Ganglioside GM3	Others	Metabolic Disease
Ganglioside GM3 is a precursor of a-, b-, and c-series gangliosides, interacts with transmembrane receptors such as the epidermal growth factor and insulin receptors, and regulates receptor functions by creating a specialized lipid environment. Ganglioside GM3 is synthesized by GM3 synthase and can be used for the research of hypercholesterolemia .

HY-18764

BpV(pic) potassium hydrate	PTEN	Metabolic Disease
BpV(pic) potassium hydrate is a PTEN inhibitor with IC₅₀ 31 nM. BpV(pic) potassium hydrate is also an insulin simulator that activates insulin receptor kinase in cultured liver cancer cells, stimulates adipogenesis in adipocytes, and inhibits the dephosphorylation of autophosphorylated insulin receptors and epidermal growth factor receptors in rat hepatosomes .

HY-162099

VEGFR-IN-4	EGFR	Cancer
VEGFR-IN-4 (Compound 6e) is an epidermal growth factor receptor (EGFR) inhibitor. VEGFR-IN-4 has potent antiproliferative activity with an IC₅₀ value of 24.6nM against HCC827 cells .

HY-100214

EAI001	EGFR	Cancer
EAI001 is a potent, selective mutant epidermal growth factor receptor (EGFR) allosteric inhibitor with an IC₅₀ value of 24 nM for EGFR ^L858R/T790M. EAI001 can be used for research of cancer .

HY-N8473

Pericosine A (+)-Pericosine A	Topoisomerase	Cancer
Pericosine A ((+)-Pericosine A) is a topoisomerase II (Topoisomerase II) inhibitor that can be isolated from the Periconia byssoides strain. Pericosine A has significant antitumor activity in vitro and in vivo and can be used in cancer research. Pericosine A also inhibits the protein kinase epidermal growth factor receptor .

HY-19909

NRC-2694	EGFR	Cancer
NRC-2694 is an epidermal growth factor receptor (EGFR) antagonist with anti-cancer and anti-proliferative properties. NRC-2694 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-P1799

[pTyr5] EGFR (988-993)	Phosphatase	Others
[pTyr5] EGFR (988-993) is derived from the autophosphorylation site (Tyr992) of epidermal growth factor receptor (EGFR 988-993). [pTyr5] EGFR (988-993) is often complexed with the catalytically inactive protein-tyrosine phosphate 1B (PTP1B) .

HY-P9985

Disitamab vedotin 1 Publications Verification RC48	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity .

HY-P1799A

[pTyr5] EGFR (988-993) (TFA)	Phosphatase	Others
[pTyr5] EGFR (988-993) TFA is derived from the autophosphorylation site (Tyr992) of epidermal growth factor receptor (EGFR 988-993). [pTyr5] EGFR (988-993) TFA is often complexed with the catalytically inactive protein-tyrosine phosphate 1B (PTP1B) .

HY-144048

EGFR-IN-31	EGFR	Cancer
EGFR-IN-31 is a potent inhibitor of EGFR. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-31 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185298A1, compound 2) .

HY-144049

EGFR-IN-32	EGFR	Cancer
EGFR-IN-32 is a potent inhibitor of EGFR. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-32 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185297A1, compound 2) .

HY-139300

Epitinib HMPL-813	EGFR	Cancer
Epitinib is an orally active and selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) designed for optimal brain penetration. Epitinib can be used for the research of cancer . Epitinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-P99268

Seribantumab SAR 256212; MM 121; Anti-Human ERBB3/ErbB 3 Recombinant Antibody	EGFR Apoptosis	Cancer
Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets HER3. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models .

HY-164202

ORM-5029	Antibody-Drug Conjugates (ADCs)	Cancer
ORM-5029 is a first-in-class human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate (ADC) comprised of SMol006, a highly potent GSPT1 degrader, conjugated to Pertuzumab (HY-P9912). ORM-5029 can be used for study of cancer .

HY-149517

EGFR/BRAFV600E-IN-2	EGFR	Cancer
E07 aptamer is an aptamer that targets human epidermal growth factor receptor (hEGFR). E07 aptamer can compete with EGF for binding, binds to a novel epitope on EGFR. E07 aptamer binds to cells expressing EGFR, blocks receptor autophosphorylation, and prevents proliferation of tumor cells in three-dimensional matrices. E07 aptamer can be used for tomor disease research .

HY-150610

EGFR-IN-69	EGFR	Cancer
EGFR-IN-69 (compound 17g) is a potent EGFR inhibitor, with IC₅₀ values of 4.3, 6.6 and 25.6 nM against EGFR ^{L858R/T790M/C797S}, EGFR ^L858R/T790M, and EGFR ^{19del/T790M/C797S}, respectively. EGFR-IN-69 can be used for non-small-cell-lung-cancer (NSCLC) research .

HY-157579

MS154N	PROTACs EGFR	Cancer
MS154N (compound 28) is the negative control of MS39 (HY-157581). MS154N is composed of PROTAC target protein ligand EGFR ligand-11 (HY-168305) (red part), E3 ligase ligand 4-Hydroxy-2-(1-methyl-2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (HY-W441376) (blue part) and PROTAC Linker 8-Iodooctan-1-amine (HY-168306) (black part), among which the conjugate of E3 ubiquitin ligase ligand + Linker is Me-Thalidomide-O-C8-NH2 (HY-168307) .

HY-157581

MS39	PROTACs EGFR	Cancer
MS39 (compound 6) is a PROTAC targeting EGFR. MS39 is composed of PROTAC target protein ligand N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(piperazin-1-yl)propoxy)quinazolin-4-amine (HY-W109039) (red part), E3 ligase ligand (S,R,S)-AHPC (HY-125845) (blue part) and PROTAC Linker Undecanedioic acid (HY-W014125) (black part), among which the conjugate of E3 ubiquitin ligase ligand + Linker is (S,R,S)-AHPC-CO-C9-acid (HY-139345). MS39 reduces the expression of EGFR and downstream signaling in HCC-827 and H3255 cells. MS39 inhibits the proliferation of H3255 cells .

HY-162482

EGFR kinase inhibitor 5	EGFR Apoptosis	Inflammation/Immunology Cancer
EGFR kinase inhibitor 5 (Compound 4c) is an orally active inhibitor for epidermal growth factor receptor (EGFR) kinase, with IC₅₀ of 18.35 μM. EGFR kinase inhibitor 5 induces apoptosis. EGFR kinase inhibitor 5 exhibits anticancer and anti-inflammatory activity with low toxicity (LD₅₀ range: 500-2000 mg/kg) .

HY-162483

EGFR kinase inhibitor 6	EGFR Apoptosis	Inflammation/Immunology Cancer
EGFR kinase inhibitor 6 (Compound 4b) is an orally active inhibitor for epidermal growth factor receptor (EGFR) kinase, with IC₅₀ of 24.34 μM. EGFR kinase inhibitor 6 induces apoptosis. EGFR kinase inhibitor 6 exhibits anticancer and anti-inflammatory activity with low toxicity (LD₅₀ range: 500-2000 mg/kg) .

HY-P1855

HER2/neu (654-662) GP2	EGFR	Cancer
HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers .

HY-116138

RG-14467	Others	Others
RG-14467 is an epidermal growth factor receptor tyrosine kinase inhibitor with activity that inhibits enzyme activity. RG-14467 has similar inhibition kinetics to Lavendustin-A, with a dissociation constant of 3.4μM for the initial rapidly formed complex and an overall dissociation constant estimated to be less than or equal to 30nM, and is a partially competitive inhibitor for ATP.

HY-139300A

Epitinib succinate HMPL-813 succinate	EGFR	Cancer
Epitinib succinate is an orally active and selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) designed for optimal brain penetration. Epitinib succinate can be used for the research of cancer . Epitinib (succinate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-145867

EGFR-IN-45	Topoisomerase EGFR CDK Apoptosis	Cancer
EGFR-IN-45 is a potent epidermal growth factor receptor (EGFR) pan inhibitor, with IC₅₀s of 0.4 µM and 1.6 µM for EGFR and CDK2, respectively. EGFR-IN-45 also inhibit Topo I and Topo II. EGFR-IN-45 arrests cancer cells in the pre-G1 phase and induces apoptosis .

HY-150781

EGFR-IN-71	EGFR	Cancer
EGFR-IN-71 is a potent narrow spectrum epidermal growth factor receptor (EGFR) inhibitor with IC₅₀ values of 3.7 μM. EGFR-IN-71 can be used for researching chordoma . EGFR-IN-71 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-129510

4-Methyl erlotinib	EGFR	Cancer
4-Methyl erlotinib, is a potent and selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. 4-Methyl erlotinib potently inhibits EGF-mediated tumor cell mitosis by reducing EGFr-specific tyrosine phosphorylation. Using a mouse model of human tumor transplantation, 4-Methyl erlotinib demonstrated significant and sustained suppression of EGFr phosphotyrosine levels, resulting in significant growth inhibition of EGFr-dependent human cancers .

HY-164487

JBJ-08-178-01	EGFR	Cancer
JBJ-08-178-01 is a mutant-selective tyrosine kinase inhibitor against human epidermal growth factor receptor 2 (HER2) with an antitumoral activity. JBJ-08-178-01 reduces both the kinase activity and protein levels of HER2 by inducing proteasomal degradation of the receptor in lung cancer. JBJ-08-178-01 is promising for research of non-small-cell lung cancer .

HY-120857

BPIQ-II hydrochloride PD 158294	Others	Others
BPIQ-II is a linear imidazoloquinazoline that potently inhibits the tyrosine kinase activity of the epidermal growth factor receptor (EGFR; IC₅₀=8 pM). It is selective for EGFR over an assortment of other tyrosine and serine/threonine kinases. Cellular studies indicate that BPIQ-II can enter cells and very selectively shut down EGF-stimulated signal transmission by binding competitively at the ATP site of EGFR.

HY-161633

PROTAC EGFR degrader 11	PROTACs EGFR FAK	Cancer
PROTAC EGFR degrader 11 (Compound B71) is a PROTAC degrader for epidermal growth factor receptor (EGFR), with DC₅₀ <100 nM. PROTAC EGFR degrader 11 binds CRBN-DDB1 with a K_i of 36 nM. PROTAC EGFR degrader 11 degrades EGFR, focal adhesion kinase (FAK), and RSK1, inhibits the proliferation of BaF3 wild type and EGFR mutants, with IC₅₀ <100 nM.

HY-163417

HER2-IN-15	EGFR	Cancer
HER2-IN-15 (Compound 1) is an inhibitor for HER2, which inhibits the Her YVMA exon 20 insertion mutation (HER2 YVMA) with an IC₅₀ <200 nM. HER2-IN-15 inhibits proliferation of HER2 YVMA mutated BaF3 cells with an IC₅₀ <200 nM and amliorates non-small-cell lung cancer (NSCLC) .

HY-163418

HER2-IN-17	EGFR	Cancer
HER2-IN-17 (Compound 2) is an inhibitor for HER2, which inhibits the Her YVMA exon 20 insertion mutation (HER2 YVMA) with an IC₅₀ <200 nM. HER2-IN-17 inhibits proliferation of HER2 YVMA mutated BaF3 cells with an IC₅₀ <200 nM and amliorates non-small-cell lung cancer (NSCLC) .

HY-163420

HER2-IN-16	EGFR	Cancer
HER2-IN-16 (Compound 14) is an inhibitor for HER2, which inhibits the Her YVMA exon 20 insertion mutation (HER2 YVMA) with an IC₅₀ <200 nM. HER2-IN-16 inhibits proliferation of HER2 YVMA mutated BaF3 cells with an IC₅₀ <200 nM and amliorates non-small-cell lung cancer (NSCLC) .

HY-168514

SOS1/EGFR-IN-2	EGFR	Cancer
SOS1/EGFR-IN-2 (Compound 4) is a SOS1 and EGFR dual inhibitor with IC₅₀s of 8.3 and 14.6 nM, respectively. SOS1/EGFR-IN-2 exhibits significant antiproliferative effect on the cancer cells haboring various KRAS mutants .

Cat. No.	Product Name

HY-L075

Anti-Lung Cancer Compound Library

1,933 compounds

Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers.

As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy.

MCE offers a unique collection of 1,933 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

HY-L074

Anti-Breast Cancer Compound Library

2,049 compounds

Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC).

Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer.

MCE supplies a unique collection of 2,049 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Cat. No.	Product Name	Target	Research Area

HY-P1855

HER2/neu (654-662) GP2	EGFR	Cancer
HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers .

HY-103291

Sar-[D-Phe8]-des-Arg9-Bradykinin	Bradykinin Receptor	Inflammation/Immunology Endocrinology
Sar-[D-Phe8]-des-Arg9-Bradykinin is a agonist of B1 receptor. Sar-[D-Phe8]-des-Arg9-Bradykinin selectively amplifies the contractile response when incubation with human recombinant interleukin-1 β (IL-1 β) in rabbit aortic rings .

HY-P1845

PACAP-38 (31-38), human, mouse, rat	ERK EGFR Reactive Oxygen Species Calcium Channel	Neurological Disease
PACAP-38 (31-38), human, mouse, rat is a PAC₁ receptor activator and increases the α-secretase activity. PACAP-38 (31-38), human, mouse, rat elevates cytosolic Ca ²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP-38 (31-38), human, mouse, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP-38 (31-38), human, mouse, rat can be used for neurotrophic and neuroprotective research .

HY-P1845A

PACAP-38 (31-38), human, mouse, rat TFA	ERK EGFR Reactive Oxygen Species Calcium Channel	Neurological Disease
PACAP-38 (31-38), human, mouse, rat TFA is a PAC₁ receptor activator and increases the α-secretase activity. PACAP-38 (31-38), human, mouse, rat TFA elevates cytosolic Ca ²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP-38 (31-38), human, mouse, rat TFA demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP-38 (31-38), human, mouse, rat TFA can be used for neurotrophic and neuroprotective research .

HY-P1085

Epidermal Growth Factor Receptor Peptide (985-996)	EGFR	Cancer
Epidermal Growth Factor Receptor Peptide (985-996) is an amino acid peptide fragment derived from positions 985-996 in epidermal growth factor receptor (EGFR) .

HY-P1799

[pTyr5] EGFR (988-993)	Phosphatase	Others
[pTyr5] EGFR (988-993) is derived from the autophosphorylation site (Tyr992) of epidermal growth factor receptor (EGFR 988-993). [pTyr5] EGFR (988-993) is often complexed with the catalytically inactive protein-tyrosine phosphate 1B (PTP1B) .

HY-P1799A

[pTyr5] EGFR (988-993) (TFA)	Phosphatase	Others
[pTyr5] EGFR (988-993) TFA is derived from the autophosphorylation site (Tyr992) of epidermal growth factor receptor (EGFR 988-993). [pTyr5] EGFR (988-993) TFA is often complexed with the catalytically inactive protein-tyrosine phosphate 1B (PTP1B) .

Cat. No.	Product Name	Target	Research Area

HY-P9905

Cetuximab 30+ Cited Publications C225	Radionuclide-Drug Conjugates (RDCs) EGFR	Cancer
Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a K_d of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity .

HY-P99268

Seribantumab SAR 256212; MM 121; Anti-Human ERBB3/ErbB 3 Recombinant Antibody	EGFR Apoptosis	Cancer
Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets HER3. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models .

HY-P99941

Retifanlimab	PD-1/PD-L1	Cancer
Retifanlimab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). Retifanlimab can be used for the research of gastroesophageal adenocarcinoma (GEA) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-18963

Lavendustin A RG-14355	Structural Classification Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Phenols Polyphenols Disease Research Fields Cancer	EGFR
Lavendustin A (RG-14355) is a potent, selective and ATP-competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, with an IC₅₀ of 11 nM. Lavendustin A does not inhibit protein kinase A or C. Lavendustin A can suppress VEGF-induced angiogenesis .

HY-N8473

Pericosine A (+)-Pericosine A	Structural Classification Natural Products Microorganisms Source classification	Topoisomerase
Pericosine A ((+)-Pericosine A) is a topoisomerase II (Topoisomerase II) inhibitor that can be isolated from the Periconia byssoides strain. Pericosine A has significant antitumor activity in vitro and in vivo and can be used in cancer research. Pericosine A also inhibits the protein kinase epidermal growth factor receptor .

Species:	Human (12) Rhesus Macaque (3) Mouse (2) Rat (1) Cynomolgus (2) Canine (1)
Tag:	His (15) Strep (1) Myc (1) GST (4) Fc (4)
Source:	HEK293 (13) Sf9 insect cells (7) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P70189

	EGFR vIII Protein, Human (HEK293, His) rHuepidermal growth factor receptor/EGFR vIII, His; epidermal growth factor receptor; EGFR; Proto-oncogene c-ErbB-1; receptor tyrosine-protein kinase erbB-1; EGFR	Human	HEK293
	The EGFRvIII protein is a transmembrane glycoprotein in the protein kinase superfamily that acts as a receptor for epidermal growth factor. It acts on the cell surface, binds to epidermal growth factor, triggers receptor dimerization and tyrosine autophosphorylation, and promotes cell proliferation. EGFR vIII Protein, Human (HEK293, His) is the recombinant human-derived EGFR vIII protein, expressed by HEK293 , with C-6*His labeled tag. The total length of EGFR vIII Protein, Human (HEK293, His) is 354 a.a., with molecular weight of 61-75 kDa.

HY-P72988

	EGFR Protein, Mouse (HEK293, Fc) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Mouse	HEK293
	The EGFR protein is a receptor tyrosine kinase that binds EGF family ligands and activates multiple signaling cascades. Ligand binding induces receptor homo- or heterodimerization, leading to autophosphorylation and recruitment of adapter proteins (such as GRB2). EGFR Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived EGFR protein, expressed by HEK293 , with C-hFc labeled tag. The total length of EGFR Protein, Mouse (HEK293, Fc) is 623 a.a., with molecular weight of ~142.57 kDa.

HY-P72989

	EGFR Protein, Mouse (HEK293, His) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Mouse	HEK293
	The EGFR protein is a receptor tyrosine kinase that binds EGF family ligands and activates multiple signaling cascades. Ligand binding induces receptor homo- or heterodimerization, leading to autophosphorylation and recruitment of adapter proteins (such as GRB2). EGFR Protein, Mouse (HEK293, His) is the recombinant mouse-derived EGFR protein, expressed by HEK293 , with C-10*His labeled tag.

HY-P72990

	EGFR Protein, Rat (HEK293, His) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Rat	HEK293
	EGFR Protein is a receptor tyrosine kinase that binds to ligands of the EGF family.EGFR Protein is involved in the regulation of NF-kappa-B , RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs signaling pathways.EGFR Protein has calmodulin binding activity, epidermal growth factor binding activity and epidermal growth factor activating receptor activity.EGFR Protein, Rat (HEK293, His) is the recombinant rat-derived EGFR protein, expressed by HEK293 , with C-His labeled tag.

HY-P72987

	EGFR Protein, Human (sf9, His-GST) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	Sf9 insect cells
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Human (sf9, His-GST) is the recombinant human-derived EGFR protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag. The total length of EGFR Protein, Human (sf9, His-GST) is 543 a.a., with molecular weight of ~89.1 kDa.

HY-P70608

	EGFR vIII Protein, Human (HEK293, Fc) 1 Publications Verification epidermal growth factor receptor; Proto-oncogene c-ErbB-1; receptor tyrosine-protein kinase erbB-1; EGFR; ERBB; ERBB1; HER1	Human	HEK293
	The EGFR vIII protein is a transmembrane glycoprotein in the protein kinase superfamily that acts as a receptor for epidermal growth factor. It acts on the cell surface, binds to epidermal growth factor, triggers receptor dimerization and tyrosine autophosphorylation, and promotes cell proliferation. EGFR vIII Protein, Human (HEK293, Fc) is the recombinant human-derived EGFR vIII protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P74177

	EGFR Protein, Human (621a.a, HEK293, Fc) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	HEK293
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Human (621a.a, HEK293, Fc) is the recombinant human-derived EGFR protein, expressed by HEK293 , with C-hFc labeled tag. The total length of EGFR Protein, Human (621a.a, HEK293, Fc) is 621 a.a., with molecular weight of 110-160 kDa.

HY-P70613

	EGFR Protein, Human (621a.a, HEK293, His) epidermal growth factor receptor; Proto-oncogene c-ErbB-1; receptor tyrosine-protein kinase erbB-1; EGFR; ERBB; ERBB1; HER1	Human	HEK293
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Human (621a.a, HEK293, His) is the recombinant human-derived EGFR protein, expressed by HEK293 , with C-6*His labeled tag. The total length of EGFR Protein, Human (621a.a, HEK293, His) is 621 a.a., with molecular weight of 90-120 kDa.

HY-P72986

	EGFR Protein, Canine (sf9, His) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Canine	Sf9 insect cells
	EGFR Protein is a receptor tyrosine kinase that binds to ligands of the EGF family. The high expression of EGFR protein can be used as a diagnostic marker for canine transitional cell carcinoma (TCC). EGFR Protein participate in the NF-kappa-B signaling pathway. The high expression of EGFR protein can be used as a diagnostic marker for canine transitional cell carcinoma (TCC). EGFR Protein, Canine (sf9, His) is the recombinant canine-derived EGFR protein, expressed by Sf9 insect cells , with C-His labeled tag. The total length of EGFR Protein, Canine (sf9, His) is 618 a.a., with molecular weight of ~87.2 kDa.

HY-P700485

	EPS15 Protein, Human (His) Eps15 epidermal; growth factor receptor pathway substrate 15; 2410112D09Rik; epidermal growth factor receptor substrate 15; epidermal growth factor pathway substrate 15; protein AF-1p	Human	E. coli
	EPS15 is a multifunctional protein that regulates cell growth, controls mitotic signaling, and contributes to receptor tyrosine kinase (RTK) internalization, particularly affecting EGFR. As a clathrin adapter, EPS15 is critical for the assembly and maturation of clathrin-coated pits (CCP), affecting the endocytosis of molecules such as ITGB1 and transferrin receptor (TFR). EPS15 Protein, Human (His) is the recombinant human-derived EPS15 protein, expressed by E. coli , with N-6*His labeled tag.

HY-P73517

	EGFR Protein, Human (Biotinylated, 621a.a, HEK293, His) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	HEK293
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Human (Biotinylated, 621a.a, HEK293, His) is the recombinant human-derived EGFR protein, expressed by HEK293 , with C-His labeled tag. The total length of EGFR Protein, Human (Biotinylated, 621a.a, HEK293, His) is 621 a.a., with molecular weight of ~99.5 kDa.

HY-P75259

	EGFR Protein, Cynomolgus (sf9, His) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Cynomolgus	Sf9 insect cells
	EGFR Protein is a receptor tyrosine kinase that binds to ligands of the EGF family. EGFR Protein is involved in the regulation of NF-kappa-B , RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs signaling pathways. EGFR Protein has calmodulin binding activity, epidermal growth factor binding activity and epidermal growth factor activating receptor activity. EGFR Protein, Cynomolgus (sf9, His) is the recombinant cynomolgus-derived EGFR protein, expressed by Sf9 insect cells , with C-His labeled tag. The total length of EGFR Protein, Cynomolgus (sf9, His) is 621 a.a., with molecular weight of ~70.1 kDa.

HY-P75260

	EGFR Protein, Cynomolgus (HEK293, His) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Cynomolgus	HEK293
	EGFR Protein is a receptor tyrosine kinase that binds to ligands of the EGF family. EGFR Protein is involved in the regulation of NF-kappa-B , RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs signaling pathways. EGFR Protein has calmodulin binding activity, epidermal growth factor binding activity and epidermal growth factor activating receptor activity. EGFR Protein, Cynomolgus (HEK293, His) is the recombinant human-derived EGFR protein, expressed by HEK293 , with C-His labeled tag. The total length of EGFR Protein, Cynomolgus (HEK293, His) is 621 a.a., with molecular weight of ~93.8 kDa.

HY-P702751

	EGFR Protein, Human (sf9, GST) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	Sf9 insect cells
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Human (sf9, GST) is the recombinant human-derived EGFR, expressed by Sf9 insect cells , with GST labeled tag. The total length of EGFR Protein, Human (sf9, GST) is 543 a.a.,

HY-P75256

	EGFR Protein, Rhesus Macaque (sf9, His) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Rhesus Macaque	Sf9 insect cells
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Rhesus Macaque (sf9, His) is the recombinant Rhesus Macaque-derived EGFR protein, expressed by Sf9 insect cells , with C-His labeled tag.

HY-P75257

	EGFR Protein, Rhesus Macaque (HEK293, His) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Rhesus Macaque	HEK293
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Rhesus Macaque (HEK293, His) is the recombinant Rhesus Macaque-derived EGFR protein, expressed by HEK293 , with C-10*His labeled tag.

HY-P75258

	EGFR Protein, Rhesus Macaque (HEK293, Fc) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Rhesus Macaque	HEK293
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Rhesus Macaque (HEK293, Fc) is the recombinant Rhesus Macaque-derived EGFR protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P700409

	EGFR Protein, Human (621a.a, HEK293, N-His, C-Myc) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	HEK293
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Human (621a.a, HEK293, N-His, C-Myc) is the recombinant human-derived EGFR protein, expressed by HEK293 , with C-Myc, N-10*His labeled tag. The total length of EGFR Protein, Human (621a.a, HEK293, N-His, C-Myc) is 621 a.a., with molecular weight of 73.6 kDa.

HY-P702832

	EGFR Protein, Human (T790M, L858R, sf9, Strep, GST, His) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	Sf9 insect cells

HY-P702831

	EGFR Protein, Human (C797S, T790M, L858R, sf9, GST) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	Sf9 insect cells
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Human (C797S, T790M, L858R, sf9, GST) is the recombinant human-derived EGFR, expressed by Sf9 insect cells , with N-GST labeled tag. ,

HY-P700693

	CLEC14A Protein, Human (HEK293, His) epidermal growth factor receptor 5; EGFR-5; EGFR 5; EGFR5; C14orf27; UNQ236; PRO269; CEG1	Human	HEK293

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-15772S3

Asandeutertinib
Asandeutertinib (Osimertinib-d3; AZD-9291-d3) is a epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, with antineoplastic effect .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80648

	EGFR Antibody (YA775) EGFR; ERBB; ERBB1; HER1; epidermal growth factor receptor; Proto-oncogene c-ErbB-1; receptor tyrosine-protein kinase erbB-1	WB, ICC/IF, IP	Human, Monkey
	EGFR Antibody (YA775) is a non-conjugated and Mouse origined monoclonal antibody about 134 kDa, targeting to EGFR (6H11). It can be used for WB,ICC/IF,IP assays with tag free, in the background of Human, Monkey.

HY-P80808

	Phospho-EGFR (Tyr1068) Antibody EGFR; ERBB; ERBB1; HER1; epidermal growth factor receptor; Proto-oncogene c-ErbB-1; receptor tyrosine-protein kinase erbB-1	WB, IHC-F, IHC-P, ICC/IF	Human
	Phospho-EGFR (Tyr1068) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 134 kDa, targeting to Phospho-EGFR (Tyr1068). It can be used for WB,IHC-F,IHC-P,ICC/IF assays with tag free, in the background of Human.

HY-P80809

	Phospho-EGFR (Tyr1092) Antibody EGFR; ERBB; ERBB1; HER1; epidermal growth factor receptor; Proto-oncogene c-ErbB-1; receptor tyrosine-protein kinase erbB-1	WB, IHC-P	Human, Mouse, Rat
	Phospho-EGFR (Tyr1092) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 134 kDa, targeting to Phospho-EGFR (Tyr1092). It can be used for WB,IHC-P assays with tag free, in the background of Human, Mouse, Rat.

HY-P80810

	Phospho-EGFR (Tyr1173) Antibody EGFR; ERBB; ERBB1; HER1; epidermal growth factor receptor; Proto-oncogene c-ErbB-1; receptor tyrosine-protein kinase erbB-1	WB, IHC-F, IHC-P, ICC/IF, IP	Human
	Phospho-EGFR (Tyr1173) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 134 kDa, targeting to Phospho-EGFR (Tyr1173). It can be used for WB,IHC-F,IHC-P,ICC/IF,IP assays with tag free, in the background of Human.

HY-P81420

	GRB7 Antibody (YA1165) B47; epidermal growth factor receptor GRB 7; GRB7 adapter protein; GRB7	IHC-P	Human
	GRB7 Antibody (YA1165) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1165), targeting GRB7. GRB7 Antibody (YA1165) can be used for IHC-P experiment in human background.